Nurix Therapeutics announced that its CEO Arthur T. Sands will participate in fireside chats at the RBC Global Healthcare Conference (May 20, 2026) and Jefferies Global Healthcare Conference (June 3, 2026). The company is advancing targeted protein degradation medicines for oncology and autoimmune diseases, with clinical-stage programs including BTK degraders and CBL-B inhibitors, alongside partnerships with Sanofi, Gilead, and Pfizer.

Nurix Therapeutics presented preclinical data at AACR 2026 demonstrating advances across its oncology pipeline, including pan-mutant BRAF degrader NRX-0305, CBL-B inhibitor NX-1607, and AURKA degrader NRX-4972. The data showcase the potential of targeted protein degradation therapies to overcome limitations of traditional inhibitors, with NRX-0305 showing 142% lifespan extension in resistant melanoma models and NRX-4972 achieving 60% survival in SCLC models compared to 0% for existing AURKA inhibitors.

The follicular lymphoma drug development pipeline is experiencing significant growth with 45+ companies actively developing 50+ pipeline therapies. Major pharmaceutical players including AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, and others are advancing promising candidates through various clinical trial phases, with approximately 5+ drugs in late-stage development. The emerging therapeutic landscape shows a shift toward targeted, oral, and patient-centric therapies with diverse mechanisms of action including protein degraders, kinase inhibitors, and immune-mediated approaches.

Nurix Therapeutics reported Q1 2026 financial results with revenue of $6.3 million (down from $18.5 million YoY) and net loss of $87.2 million. The company is advancing its registrational program for bexobrutideg with Phase 2 DAYBreak CLL-201 enrollment ongoing for accelerated approval in relapsed/refractory CLL, and plans to initiate Phase 3 DAYBreak CLL-306 by mid-2026. Nurix maintains a strong cash position of $540.7 million and is expanding bexobrutideg into immunology/inflammation indications with a new tablet formulation targeting 2026 IND submission.

Redmile Group increased its stake in Nurix Therapeutics by 4.4 million shares worth $63.43 million, bringing its total position to 11.31% of its assets. Despite the stock being down 6.5% over the past year, the fund's conviction in the biotech company reflects confidence in its lead BTK degrader program entering a registrational trial with strong Phase 1 data showing 83% objective response rate.

The precision oncology market is projected to grow from $110 billion to $225.65 billion by 2032, driven by Big Pharma's race to acquire registration-ready assets ahead of a $170 billion patent cliff through 2030. Several biotech companies are advancing promising clinical programs: Oncolytics Biotech strengthened its leadership team for pelareorep development in gastrointestinal cancers; Nurix is executing pivotal studies for its BTK degrader bexobrutideg in chronic lymphocytic leukemia; Erasca reported early clinical data for its pan-RAS molecular glue ERAS-0015; Foghorn raised $50 million for its SMARCA4-targeting program; and ORIC presented strong Phase 1b data for rinzimetostat in prostate cancer.

Nurix Therapeutics reported promising Phase 1 trial results for bexobrutideg, an investigational drug for relapsed or refractory chronic lymphocytic leukemia, showing an 83% objective response rate and a median progression-free survival of 22.1 months.

Nurix Therapeutics will host a webcast on December 8, 2025, to present new clinical data on bexobrutideg (NX-5948), an investigational BTK degrader for treating chronic lymphocytic leukemia and Waldenström macroglobulinemia.

Nurix Therapeutics will present updated clinical data on bexobrutideg, a novel BTK degrader, at the ASH Annual Meeting, showcasing results in chronic lymphocytic leukemia and Waldenström macroglobulinemia treatments.

Nurix Therapeutics raised $250 million through a stock offering to fund clinical development of drug candidates targeting chronic lymphocytic leukemia and potential autoimmune indications.

Nurix Therapeutics launched a pivotal Phase 2 clinical trial (DAYBreak) for bexobrutideg, a potential BTK degrader treatment for relapsed or refractory chronic lymphocytic leukemia, with plans for a Phase 3 confirmatory study in 2026.

Nurix Therapeutics presented Phase 1a clinical data for NX-1607, a first-in-class oral CBL-B inhibitor, showing promising anti-tumor activity across multiple solid tumor types with evidence of immune activation and clinical benefits.